Journal article icon

Journal article

Safety and efficacy of Tofacitnib in patients with active psoriatic arthritis: Interim analysis of OPAL balance, an open-label, long-term extension study

Abstract:

Introduction:
Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis (PsA). We report the interim safety, tolerability, and efficacy of tofacitinib in PsA patients in OPAL Balance, a 3-year, open-label, long-term extension study (data cut-off: August 2017; database not locked, data may change).


Methods:
Eligible patients from two phase (P) 3 (P3) tofacitinib PsA studies (OPAL Broaden, NCT01877668; O...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Subgroup:
Botnar Research Centre
Role:
Author
ORCID:
0000-0002-4756-663X
Expand authors...
Publisher:
Springer Publisher's website
Journal:
Rheumatology and Therapy Journal website
Publication date:
2020-06-06
Acceptance date:
2020-04-21
DOI:
EISSN:
2198-6584
ISSN:
2198-6584
Pubs id:
1102526
Local pid:
pubs:1102526

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP